Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate <scp>Pan‐Transporter</scp> Inhibition Signatures-Reference-Cited by-同舟云学术

Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures

Published:2022-08-10 Issue:5 Volume:113 Page:986-1002
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Rodrigues A.D.¹

Affiliation:

1. Pharmacokinetics & Drug Metabolism, Medicine Design, Worldwide Research & Development Pfizer Inc Groton Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2713

Reference106 articles.

1. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

2. Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions

3. Transporter-Mediated Drug-Drug Interactions and Their Significance

4. Examination of Physiologically‐Based Pharmacokinetic Models of Rosuvastatin

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significant increases in detection capability for assessment of organic anion transporting polypeptide-mediated drug-drug interaction in cynomolgus monkeys by modifying pretreatment of Coproporphyrin I and III, and glycochenodeoxycholate-3-sulfate in plasma;Analytica Chimica Acta;2024-09

2. Albumin-Mediated Drug Uptake by Organic Anion Transporter 1/3 Is Real: Implications for the Prediction of Active Renal Secretion Clearance;Molecular Pharmaceutics;2024-08-21

3. Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies;Pharmaceutics;2024-07-26

4. Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon;Pharmaceutics;2024-06-25

5. Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective;Clinical Pharmacokinetics;2024-06